Pfizer launches Dupuytren’s contracture drug Xiapex in UK

Pfizer has announced the UK availability of Xiapex, its innovative new treatment option for Dupuytren's contracture.

The drug has been ratified as the first injectable treatment for the condition to be launched in Britain after it demonstrated its efficacy in pivotal clinical trials.

Dupuytren's contracture is a consequence of the progressive ailment known as Dupuytren's disease, which causes an excess build-up of collagen under the skin in hands and causes fingers to become permanently contracted towards the palm.

It is hoped that this new drug can offer a viable alternative to surgery when treating a condition that can be significantly detrimental to patients' quality of life.

Jonathan Jones, medical director of the speciality care business unit at Pfizer, said: "The development of a new treatment like Xiapex is an important step forward for patients with Dupuytren's contracture."

Earlier this week, Pfizer announced the sale of its drug delivery business unit Capsugel to Kohlberg Kravis Roberts, an international investment company.